Survival following relapse in childhood haematological malignancies diagnosed in 1974–2003 in Yorkshire, UK

RG Feltbower*,1, SE Kinsey2, M Richards2, G Shenton2, MP Michelagnoli3 and PA McKinney1
1Paediatric Epidemiology Group, Centre for Epidemiology and Biostatistics, 30–32 Hyde Terrace, University of Leeds, Leeds LS2 9LN, UK; 2Paediatric Oncology & Haematology, Leeds Teaching Hospitals NHS Trust, Beckett St, Leeds LS9 7TF, UK; 3University College Hospital, 235 Euston Road, London, NW1 2BU, UK

We examined population-based information on relapsed haematological cancers, investigating factors that might influence both overall survival and survival following relapse among the 1177 children (0–14 years) diagnosed with a haematological malignancy in Yorkshire from 1974 to 2003, of whom 342 (29%) relapsed at least once. Leukaemia patients from more deprived areas were significantly less likely to relapse (odds ratio = 0.54, 95% confidence interval 0.32–0.93 for most deprived quintile vs least deprived quintile; \( P_{\text{trend}} = 0.06 \)), especially those with acute myeloid leukaemia (\( P = 0.04 \)). Neither ethnic group nor distance to the main treatment centre was associated with risk of relapse. Overall, patients who relapsed at least once had 5-year survival rates of 46% (41–51%) compared with 79% (76–81%) of those who did not. Five-year survival rates from the time of first relapse increased from 20% in 1974–1983 to 45% in 1984–2003. Length of first remission was a strong predictor of survival for leukaemia with a 46% reduced risk of death for every additional year of event-free survival. Of children who experienced a relapse, 46% survived at least 5 years, whereas just under half of patients survived 5 years beyond disease recurrence. This provides a baseline for future comparisons and demonstrates that relapsed childhood cancer need not imply a poor outcome.

British Journal of Cancer (2007) 96, 1147 – 1152. doi:10.1038/sj.bjc.6603667 www.bjcancer.com
Published online 6 March 2007
© 2007 Cancer Research UK

Keywords: relapse; risk factors; survival; children

Population based survival rates now exceed 70% for all malignancies diagnosed under the age of 15 in the UK (Coleman et al, 1999), having improved steadily since 1950 (Stiller and Bunch, 1990). Despite improved prognosis, an appreciable number of patients still fail first-line treatment, with 75% of deaths occurring in paediatric oncology units (Al-Asiri et al, 1992) and among long-term survivors of childhood cancer in a population-based series (Robertson et al, 1994) being due to recurrent disease.

In an audit of care carried out in the 1990s in a tertiary paediatric oncology unit in Leeds (unpublished), relapsed disease accounted for up to 50% of all inpatient bed occupancy, constituting a major part of the unit’s workload. Most literature on relapse concerns acute lymphoblastic leukaemia (ALL), and is almost entirely limited to patients either on a trial protocol or selected from a hospital-based series (Eden et al, 2000; Gustafsson et al, 2000; Lawson et al, 2000; Schrappe et al, 2000; Silverman et al, 2000; Tsuchida et al, 2000; Vilmer et al, 2000; Chessells et al, 2003; Roy et al, 2005), although one paper from Scandinavia has reported on the outcome following relapse ALL in a population-based cohort (Schroeder et al, 1995). A smaller number of studies have focused on relapse associated with acute myeloid leukaemia (Caspers and Creutzig, 2005; Gibson et al, 2005; Lie et al, 2005).

We examined population-based information on relapsed childhood haematological cancers, looking at factors that might influence both overall survival and survival following relapse; we also tested the local clinical impression that time to relapse was increasing in response to more intensive treatment.

MATERIALS AND METHODS

Diagnostic, clinical and demographic information on all children diagnosed under the age of 15 with a haematological malignancy from 1974 to 2003 was obtained from the Yorkshire Specialist Register of Cancer in Children and Young People, covering the former Yorkshire Regional Health Authority (Feltbower et al, 2001). Checks with adjoining childhood cancer registries and the National Registry of Childhood Tumours (Stiller et al, 1998) are carried out routinely to ensure optimum ascertainment rates. Overall, 90% of diagnoses were confirmed by histopathology, although this proportion increased substantially over time, averaging 98% since 1986. Children were actively followed up every 2 years with general practitioners and hospital records to determine their health status, treatment and any adverse outcomes such as relapse or second malignancies. Our clinical definition of ‘relapse’ was recurrent disease, either occurring locally at the same site as the initial diagnosis and/or elsewhere, and the date of this event was recorded. A cross-check with the national clinical trials database (www.ctsu.ox.ac.uk) was undertaken to ensure all

*Correspondence: Dr RG Feltbower; E-mail r.g.feltbower@leeds.ac.uk
Received 8 January 2007; revised 31 January 2007; accepted 5 February 2007; published online 6 March 2007
RESULTS

Hosmer–Lemeshow goodness-of-fit tests showed that all the models fitted the data well.

Relapse patterns

One thousand one hundred and seventy-seven children were identified, 856 with leukaemia and 321 with lymphoma. Three hundred and forty-two (29%) of these patients relapsed at least once (Table 1). Of the 18 patients diagnosed with Burkitt lymphoma, only two relapsed, so it was decided not to combine non-Hodgkin’s lymphoma (NHL; ICCC group Ib) and Burkitt lymphoma (ICCC group Ic) together in the statistical analysis.

Children with lymphoma were significantly less likely to relapse (20%) than those with leukaemia (32%): OR = 0.53 (95% CI 0.39–0.72). Median time to relapse showed some differences: patients with ALL and Hodgkin’s lymphoma relapsed after 2.2 years (range 1 month to 18 years), whereas those with acute myeloid leukaemia (AML), ‘other’ leukaemia (ICCC groups Ic–Ie), NHL and ‘other’ lymphoma (ICCC groups Ic–Ie) relapsed after 0.7–1.5 years (range 1 month to 24 years). There was no variation in time to first relapse by diagnostic period.

Factors associated with relapsed disease

Of the 200 individuals who died but never relapsed, 77 did so within 5 weeks of their diagnosis date and were excluded from the logistic regression modelling: these mainly consisted of ALL (n = 27), AML (n = 26) and NHL (n = 15).

Leukaemia

Females with ALL were significantly less likely to relapse than males (OR = 0.69; 95% CI 0.51–0.95), with AML displaying a similar but nonsignificant association (OR = 0.43; 95% CI 0.18–1.01). Older children (ages 10–14) with leukaemia had a slightly higher risk of relapse compared with 0–4 year old children (OR = 1.41; 95% CI 0.94–2.11), although this effect was not significant for any diagnostic subgroup.

Children diagnosed with leukaemia in 1984–1993 and 1994–2003 were significantly less likely to relapse than those diagnosed in 1974–1983 (Ptrend = 0.01). This effect was not entirely explained by reduced rates of early relapse: for example, the proportion of children who relapsed 3 years postdiagnosis decreased over time from 16% in 1974–1983 to 6% in 1994–2003. Patients entered into

| ICCC group | Diagnosis group | Patients alive at 31 May 2006 | Deceased patients | All registered patients |
|------------|----------------|-------------------------------|--------------------|------------------------|
| I          | Leukaemia      |                              |                    |                        |
| Ia         | Acute lymphoid leukaemia | 78 (15.2%) | 435 (84.8%) | 199 (58.0%) | 144 (42.0%) | 277 (32.4%) | 579 (67.6%) | 856 |
| Ib         | Acute myeloid leukaemia | 66 (15.0%) | 375 (85.0%) | 162 (69.8%) | 70 (30.2%) | 228 (33.9%) | 445 (66.1%) | 673 |
| Ic–e       | Other leukaemia | 12 (20.7%) | 46 (79.3%) | 31 (34.4%) | 59 (65.6%) | 43 (29.1%) | 105 (70.9%) | 148 |
| II         | Lymphoma       | 0 (0.0%) | 14 (100.0%) | 6 (26.8%) | 15 (71.4%) | 8 (17.1%) | 29 (82.9%) | 35  |
| Ila        | Hodgkin’s lymphoma | 27 (11.9%) | 200 (88.1%) | 38 (40.4%) | 56 (59.6%) | 65 (20.2%) | 256 (79.8%) | 321 |
| Iib        | Non-Hodgkin’s lymphoma | 16 (13.3%) | 104 (86.7%) | 5 (33.3%) | 10 (66.7%) | 21 (15.6%) | 114 (84.4%) | 135 |
| Ic–e       | Other lymphoma | 10 (13.5%) | 64 (86.5%) | 26 (43.3%) | 34 (56.7%) | 36 (26.9%) | 98 (73.1%) | 134 |
| Total      |                | 105 (14.2%) | 635 (85.8%) | 237 (54.2%) | 200 (45.8%) | 342 (29.1%) | 835 (70.9%) | 1177 |

*ICCC: International Classification of Childhood Cancer (Kramaróva et al, 1996). †Excluded from main analyses.
a clinical trial were significantly less likely to relapse than those who were not.

Children in the most deprived areas had a significantly lower risk of relapse than those from the most affluent areas ($P_{\text{trend}} = 0.06$; OR = 0.54, 95% CI 0.32–0.93 for most deprived quintile vs least deprived quintile). This effect was most marked for those with AML ($P_{\text{trend}} = 0.04$). No significant differences in risk of relapse were evident according to ethnic group or distance to the main treatment centre.

**Lymphoma**

No significant differences by gender were observed for lymphoma. The general pattern of a lower risk of relapse for those diagnosed more recently was observed, especially for NHL, although no significant trends were found. Trial entry was associated with a significant reduction in risk of relapse, although no consistent associations were seen with deprivation. Neither ethnic group nor distance to treatment centre influenced the risk of relapse.

**Factors associated with survival following relapse**

Median survival times for leukaemia and lymphoma following the first relapse were 1.5 and 1.15 years, respectively. Overall, patients who relapsed at least once had 5-year survival rates from diagnosis of 46% (95% CI 41–51%) compared with 79% (76–81%) for those who never relapsed. Results were similar for other diagnostic subgroups except AML, where 5-year survival rates were 30 and 46% for relapsed and nonrelapsed diseases, respectively. Survival rates for leukaemia from the time of first relapse (Figure 1) showed that only 20% of patients survived beyond 5 years if diagnosed in 1974–1983 compared with 45% if diagnosed in 1984–2003 ($P_{\text{trend}} = 0.01$). Patients with AML showed an even more dramatic improvement in 5-year survival rates, rising from 0% in 1974–1983 to 35% in 1984–1993 and 53% in 1994–2003.

Table 2 presents the hazard ratio (HR) estimates and 95% CI derived from the Cox regression analysis for the 342 patients who experienced at least one relapse episode. Results for ‘other’ leukaemia (ICCC groups Ic–e), Hodgkin’s lymphoma (IIa), NHL (Iib) and ‘other’ lymphoma (Iic–e) are not shown because of small numbers.

**Leukaemia**

Females had a nonsignificantly increased risk of death compared with males for leukaemia (HR = 1.32, 95% CI 0.96–1.82) and all other diagnostic subgroups. A significantly increased risk of death was observed for 10–14-year-olds with leukaemia compared with those aged 0–4 years (HR = 1.53, 95% CI 1.05–2.23).

For both ALL and AML, individuals diagnosed in the two most recent decades were significantly less likely to die than those diagnosed in 1974–1983 ($P_{\text{trend}} = 0.001$). No significant differences in survival were found by ethnic group, although patients treated on a trial protocol had a nonsignificantly reduced risk of death. Increasing levels of deprivation were associated with an increased risk of death for leukaemia, but no significant trends were observed for any subgroup. Time to first relapse was strongly associated with length of survival for all diagnostic subgroups: for all leukaemia combined, patients were 46% less likely to die for every additional year of event-free survival (HR = 0.54, 95% CI 0.47–0.62). Site of relapse had a significant impact on survival for ALL: testis and CNS relapses had significantly higher survival rates compared with BM. Distance to the main treatment centre did not influence survival.

**Lymphoma**

No significant difference in survival was observed for lymphoma patients by gender, age, period of diagnosis, ethnicity or distance to the main treatment centre. Trial entry did not show any beneficial effect on survival, revealing a slightly elevated risk of death. No significant trends across deprivation quintiles were observed, although individuals from the least deprived areas were least likely to die. Time to first relapse had an impact on survival, albeit less pronounced than that for leukaemia (HR = 0.87, 95% CI 0.74–1.02). No significant differences in survival were observed by site of relapse.

**DISCUSSION**

We report for the first time factors influencing the risk of relapsed childhood haematological cancer from a UK cohort spanning 30 years, together with their subsequent survival chances. Our findings indicate that 30% of leukaemia and 20% of lymphoma patients are likely to relapse at least once. Time to first relapse was similar for ALL and Hodgkin’s lymphoma, although somewhat shorter for AML, other leukaemia subtypes and NHL, but accorded with previous ALL reports (Gustafsson et al, 1987, 2000; Eden et al, 2000; Lawson et al, 2000; Schrappe et al, 2000; Silverman et al, 2000; Tsuchida et al, 2000; Vilmér et al, 2000; Chessells et al, 2003; Roy et al, 2005). There was no change in the median time to relapse for any diagnostic group across the study period, which therefore did not confirm local impressions that more children were surviving longer at the expense of more frequent relapses.

A key finding was the 46% 5-year survival rates for those who had relapsed, in contrast to 79% for those who did not relapse. This observation was seen across all diagnostic groups except AML and is consistent with recent international and UK data on ALL (Schroeder et al, 1995; Chessells, 1998; Lawson et al, 2000; Chessells et al, 2003; Roy et al, 2005), although our population-based study, as well as other diagnostic groups, included a longer follow-up period. Furthermore, almost half (45%) of leukaemia and lymphoma patients diagnosed since 1984 survived 5 years after their initial relapse episode, a striking improvement from the one in five (20%) 5-year survivors diagnosed in 1974–1983. Recurrent disease therefore need not imply a poor outcome for childhood haematological cancer.

Time to first relapse was an important prognostic indicator, in agreement with other international and UK findings for ALL (Schroeder et al, 1995; Chessells, 1998; Lawson et al, 2000; Chessells et al, 2003; Roy et al, 2005), our data indicating a 46% improvement in survival for leukaemia for every year of event-free survival since diagnosis. Localisation of relapse was also a significant prognostic factor for ALL, with testis and CNS relapses
exhibiting significantly better survival than BM relapse. Increased survival following relapse was observed for leukaemia patients entered into a clinical trial and for those diagnosed more recently. Five-year overall survival rates of 45% for patients who had relapsed in our Yorkshire cohort diagnosed in the 1990s is only marginally lower than data reported from UK ALL R1 and R2 trials showing 56% overall survival during the same period (Lawson et al, 2000; Roy et al, 2005). Equivalent postrelapse survival rates for AML showed a consistent improvement over the study period from 0% in 1974 – 1983 up to 53% in 1994 – 2003. This correlates well with a general trend in the reduction of the cumulative risk of relapse for patients on trials (Caspers and Creutzig, 2005; Lie et al, 2005) and agrees with 5-year post-relapse survival rates of around 30% reported from other UK data between 1988 and 1995 (Gibson et al, 2005). Females who had relapsed had a slightly (but not significantly) greater risk of death than males, in contrast to the usual finding that females survive longer than males for most diagnostic groups (Coleman et al, 1999); this requires confirmation in other populations.

Leukaemia patients from more deprived areas were significantly less likely to relapse initially than those from the most affluent areas, although this effect was largely restricted to AML. This novel finding is rather puzzling, as it is unlikely to be due to lack of access to treatment as most young children visit tertiary referral centres both for their main therapy and long-term follow-up; moreover, distance to treatment centre was not associated with risk of relapse. Nor could it be explained by any variation in fatality rate before reaching remission by level of deprivation. For those patients with complete stage of tumour recorded, more aggressive cancers were not related to deprivation category. Given the relatively small numbers who had relapsed with leukaemia, the associations with deprivation may be due to chance.

Females with leukaemia were less likely to relapse than males, as were younger patients, supporting previous UK findings for ALL (Lawson et al, 2000). Those diagnosed during the earliest decade (1974 – 1983) had the poorest prognosis irrespective of leukaemia subtype. NHL followed the same patterns as leukaemia in terms of the effect on relapse from sex and period of diagnosis, whereas Hodgkin’s lymphoma exhibited a nonsignificantly higher risk for female patients, and only those diagnosed in the most recent decade (1994 – 2003) had a reduced risk of relapse compared to earlier registrations.

### Table 2: Cox regression: association between risk factors and survival following relapsed childhood haematological cancer diagnosed between 1974–2003 in Yorkshire, UK

| Factor                      | Leukaemia (ICCC la – e) | ALL (ICCC a Ia) | AML (ICCC a Ib) | Lymphoma (ICCC a IIa – e) |
|-----------------------------|-------------------------|----------------|----------------|--------------------------|
| Sex                         |                         |                |                |                          |
| Males                       | 1.00                    | 1.00           | 1.00           | 1.00                     |
| Females                     | 1.32                    | 1.20           | 2.06           | 1.06                     |
| Age group                   |                         |                |                |                          |
| 0–4                         | 1.00                    | 1.00           | 1.00           | 1.00                     |
| 5–9                         | 0.98                    | 0.88           | 3.16           | 1.48                     |
| 10–14                       | 1.53                    | 1.33           | 2.59           | 1.22                     |
| Period of diagnosis         |                         |                |                |                          |
| 1974 – 1983                 | 1.00                    | 1.00           | 1.00           | 1.00                     |
| 1984 – 1993                 | 0.55                    | 0.59           | 0.95           | 1.36                     |
| 1994 – 2003                 | 0.39                    | 0.43           | 0.19           | 2.28                     |
| Entered clinical trial      |                         |                |                |                          |
| No                          | 1.00                    | 1.00           | 1.00           | 1.00                     |
| Yes                         | 0.74                    | 0.77           | 1.76           | 1.16                     |
| Ethnic group                |                         |                |                |                          |
| Non-south Asian             | 1.00                    | 1.06           | 0.22           | 1.20                     |
| South Asian                 | 0.85                    | 0.49           | 0.02           | 0.36                     |
| Deprivation                 |                         |                |                |                          |
| I (lowest)                  | 1.00                    | 1.00           | 1.00           | 1.00                     |
| II                          | 1.26                    | 1.43           | 0.51           | 4.87                     |
| IV                          | 0.97                    | 0.87           | 2.48           | 3.98                     |
| V (highest)                 | 1.25                    | 0.99           | 1.68           | 1.48                     |
| Time to 1st relapse (years) |                         |                |                |                          |
| 0.54                        | 0.54                    | 0.47           | 0.47           | 0.87                     |
| Distance to treatment hospital: ≤20 km | 1.17 | 1.00           | 1.00           | 1.00                     |
| ≥20 km                      | 1.17                    | 1.04           | 1.07           | 1.28                     |
| Site of relapse             |                         |                |                |                          |
| Bone marrow                 | 1.00                    | 1.00           | 1.00           | 1.00                     |
| Testis                      | 0.43                    | 0.35           | 0.35           | 0.91                     |
| Central Nervous system      | 0.42                    | 0.50           | 0.35           | 0.35                     |
| Other                       | 0.86                    | 0.79           | 0.62           | 0.60                     |

ALL: acute lymphoblastic leukaemia; AML: acute myeloid leukaemia; CI, confidence interval; HR, hazard ratio; aICCC: International Classification of Childhood Cancer (Kramárová et al, 1996).
The statistical power of our analyses was dependent firstly on the number of relapses observed within each diagnostic group (eg 277 out of 856 for leukaemia) and secondly by the number of deaths experienced. This precluded more detailed investigations of relapse patterns and survival trends. Also, some patients diagnosed in the most recent period will have not experienced relapsed disease due to censoring, although analyses took this into account. Details of biological markers and molecular genetics were not generally available for the Yorkshire cohort. However, biological information can be a useful tool for indicating survival chances following relapse. For instance, for relapsed ALL, the presence of 11q23 abnormalities and Ph’-positive ALL may be linked with a poorer prognosis (Vora et al, 1996; Chassells et al, 2003) whereas survivors with the TEL-AML 1 fusion transcript had an extended second remission period compared with those without (Seeger et al, 1997). Differences in the molecular characteristics of tumours occurring across deprivation quintiles may partly explain some of our findings.

The observation that almost half of all patients with any haematological malignancy (except AML) registered since 1974 who fail first-line treatment and relapse survive 5 years beyond their diagnosis and the same proportion survive 5 years beyond their initial relapse episode is an important finding as it has been achieved without an increase in the number of long-term relapse episodes: it provides a baseline figure for future studies. Links between deprivation and the risk of relapse and subsequent survival require validation in other population-based cohorts.

ACKNOWLEDGEMENTS

We are grateful to Margaret Buchan and Paula McLoughlin for data collection and the cooperation of all paediatric oncologists, physicians and general practitioners in Yorkshire. We thank Alison Franklin for comments on an earlier draft. We are also indebted to the assistance Sue Richards from the Clinical Trials Service Unit for the record linkage exercise and Dr Isabel Dos Santos Silva at the London School of Hygiene and Tropical Medicine for running the SANGRA names recognition program. Finally, we thank the Candelighters Trust for supporting the costs of running the cancer register.

REFERENCES

Al-Astri RH, Mott MG, Oakhill A (1992) Causes of death in a paediatric oncology unit. Med Pediatr Oncol 20: 315 – 320

Caspers GJL, Creutzig U (2005) Pediatric acute myeloid leukemia: international progress and future directions. Leukemia 19: 2025 – 2029

Chassells JM (1998) Relapsed lymphoblastic leukaemia in children: a continuing challenge. Br J Haematol 100: 423 – 438

Chassells JM, Veys P, Kempski H, Henley P, Leiper A, Webb D, Hann IM (2003) Long-term follow-up of relapsed childhood acute lymphoblastic leukaemia. Br J Haematol 123: 396 – 405

City of Bradford Metropolitan District Council. NAM PEHCHAN: South Asian Names (Indian Sub-continent) A computer program to identify and analyse south Asian names Version 2.1. City of Bradford Metropolitan District Council Computer Services Division, 2002

Coleman MP, Babb P, Damiecki P, Grosclaude P, Honjo S, Jones J, Knerer G, Pitard A, Quinn M, Sloggett M, De Stavola B (1999) Cancer survival trends in England and Wales, 1971 – 1995: deprivation and NHS Region. Studies in Medical and Population Subjects No. 61. The Stationery Office: London

Cummins C, Winter H, Cheng KK, Appleby P, Peto R (1999) Postcodes as useful markers of social class: population based study in 26000 British households. BMJ : 318: 843 – 845

Eden OB, Harrison G, Richards S, Lilleyman JS, Bailey CC, Chassells JM, Hann IM, Hill FG, Gibson BE (2000) Long-term follow-up of the United Kingdom Medical Research Council protocols for childhood acute lymphoblastic leukaemia, 1980 – 1997. Leukemia 14: 2307 – 2320

Feltbower RG, Moorman AV, Dovey G, Kinsey SE, McKinney PA (2001) Incidence of childhood acute lymphoblastic leukaemia in Yorkshire, UK. Lancet 358: 385 – 387

Ginery PS, Desai AA, Bostrom BC, Hutchinson RJ, Lange BJ, Nachman JB, Reeman GH, Sather VN, Steinherz FG, Trigg ME, Tubergen DG, Uckun FM (1997) Early response to therapy and outcome in childhood acute lymphoblastic leukaemia. Cancer 80: 1717 – 1726

Gibson BE, Wheatley K, Hann IM, Stevens RF, Webb D, Hills RK, De Graaf SS, Harrison CJ (2005) Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia 19: 2130 – 2138

Gustafsson G, Garwicz S, Hertz H, Johansen G, Jonmundsson G, Moe PJ, Salmi T, Seip M, Siimes MA, Yssing M (1987) A population-based study of childhood acute lymphoblastic leukaemia diagnosed from July 1981 through June 1985 in the five Nordic countries. Incidence, patient characteristics and treatment results. Acta Paediatr Scand 76: 781 – 788

Gustafsson G, Schmiegelow K, Forester E, Clausen N, Glimstien A, Jonmundsson G, Mellander L, Makiperrna A, Nygaard R, Saairen-Pihlka UM (2000) Improving outcome through two decades in childhood ALL in the Nordic countries: the impact of high-dose methotrexate in the reduction of CNS irradiation. Leukemia 14: 2267 – 2275

Hosmer DW, Lemeshow S (1989) Applied Logistic Regression. New York: John Wiley & Sons

Kramarova E, Stiller CA, Ferlay J, Parkin DM, Draper GJ, Michaelis J, Neglia J, Qureshi S (1996) International classification of childhood cancer 1996. In IARC technical report No. 29. Lyon: IARC

Lawson SE, Harrison G, Richards S, Oakhill A, Stevens R, Eden OB, Darbyshire PJ (2000) The UK experience in treating relapsed childhood acute lymphoblastic leukaemia: a report on the Medical Research Council UKALLR1 study. Br J Haematol 108: 531 – 543

Lie SO, Abrahamsson J, Clausen N, Forester E, Hasle H, Hovi L, Jonmundsson G, Mellander L, Siimes MA, Yssing M, Zeller B, Gustafsson G (2005) Long-term results in children with AML: NOPHO-AML Study Group – report of three consecutive trials. Leukemia 19: 2090 – 2100

London School of Hygiene and Tropical Medicine (1999) SANGRA: South Asian Name & Group Recognition Algorithm Version 1.1. London

Robertson CM, Hawkin MM, Kingston JE (1994) Late deaths and survival after childhood cancer – implications for cure. BMJ 309: 162 – 166

Roy A, Cargill A, Love S, Moorman AV, Stoneham S, Lim A, Darbyshire PJ, Lancaster D, Hann I, Eden T, Saha V (2005) Outcome after first relapse in childhood acute lymphoblastic leukaemia – lessons from the United Kingdom R2 trial. Br J Haematol 136: 67 – 75

Schrappe M, Reiter A, Zimmermann M, Harbott J, Ludwig WD, Henze G, Gadner H, Odenwald E, Riehm H (2000) Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Leukemia 14: 2205 – 2222

Schroeder H, Garwicz S, Kristinsson J, Siimes MA, Wesenberg F, Gustafsson G (1995) Outcome after first relapse in children with acute lymphoblastic leukaemia: a population-based study of 315 patients. Med Pediatr Oncol 25: 372 – 378

Seeger K, Buschwald S, Beyerman B, Adams HP, Kochling J, Schmid HJ, Niemeyer C, Janka G, Henze H (1997) TEL-AML 1 fusion transcript in relapsed childhood acute lymphoblastic leukaemia. Blood 90: 560a

Silverman LB, Declerck L, Gelber RD, Dalton VK, Asselin BL, Zeller RD, Clavell LA, Hurwitz CA, Moghribi A, Samson Y, Schorin MA, Lipton JM, Cohen HJ, Sallan SE (2000) Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukaemia (1981 – 1995). Leukemia 14: 2247 – 2256

Stiller CA, Allen MB, Bayne A, Brownbill P, Draper GJ, Eatock EM, Loach MJ, Vincent T (1998) United Kingdom: National Registry of Childhood Leukemia 2307 – 2320
Relapse of childhood leukaemia and lymphoma

RG Feltbower et al

British Journal of Cancer (2007) 96(7), 1147 – 1152
© 2007 Cancer Research UK